Comparative study on the use of co-trimoxazole and tetracycline in the treatment of lower respiratory tract infections.
A double-blind trial was carried out on 116 patients with lower respiratory tract infection and systemic manifestations. One group received co-trimoxazole (480 mg. trimethoprim and 2,400 mg. sulphamethoxazole daily), and the other group received 2 g. tetracycline daily. The trial, as judged by clinical improvements, the reduction of purulent sputum and the rate of eradication of infection, showed a better result with co-trimoxazole. The incidence of side-effects were higher in the group receiving tetracycline compared with those receiving co-trimoxazole.
D004338:Drug Combinations; D005260:Female; D006801:Humans; D008297:Male; D012141:Respiratory Tract Infections / Q000188:drug therapy*; D013420:Sulfamethoxazole / Q000009:adverse effects / Q000627:therapeutic use*; D013752:Tetracycline / Q000627:therapeutic use*; D014295:Trimethoprim / Q000009:adverse effects / Q000627:therapeutic use*
D004338:Drug Combinations; D014295:Trimethoprim; D013752:Tetracycline; D013420:Sulfamethoxazole